IL22 and nervous system disorder: Next, we examined the frequency of CRYAB- and EBNA1-reactive T cells in natalizumab-treated pwMS (MS-Nat; n = 59), pwMS before starting disease-modifying treatment (MS-Un; n = 25), healthy control (HC; n = 19), and other neurological disease controls (OND; n = 20) using bead-bound antigen stimulations in an IFNγ/interleukin-17A (IL-17A)/interleukin-22 (IL-22) FluoroSpot assay, which we have previously used to detect autoreactive T cells (24).